News

Hay fever treatment could improve Alzheimer's symptoms

21-Jul-08

A drug used to treat hay fever could help improve symptoms in patients with mild to moderate Alzheimer's disease, according to US research.

The study involved 183 Alzheimer’s sufferers who were randomly assigned to receive 20mg of the antihistamine dimedon, three times a day, or placebo.

After six months, the researchers found that memory, behaviour and the ability to conduct simple activities like eating improved among the patients who were taking dimebon.

The researchers, from Baylor College of Medicine in Houston, Texas, concluded that ‘the continued and increasing benefit of dimedon over the course of this study is especially important because at present no approved therapies for mild-to-moderate Alzheimer’s disease have shown increasing improvement over 12 months’.

Susan Sorensen, head of research at Alzheimer’s Society, said: ‘These initial findings imply that dimebon could be more effective than treatments currently licensed for people with Alzheimer’s, however this was a modest-sized study.

‘More substantial research is now needed, which studies more people over a longer period of time, to investigate the true value of this drug and whether it treats Alzheimer’s disease itself or just the symptoms.’

sanjay.tanday@haymarket.com

The Lancet

Comment below and tell us what you think

Comments

Imam Nilufar

21/07/2008

This sounds rather encouraging. Obviously more extensive research with side effect profile in a larger number is essential before clinical use.

Martin Gray

21/07/2008

It is a small cohort for a study to have any true reflection on outcomes don't you think? Apart from which I seem to be reading a lot of media articles about what vegetables, fruits, juices, etc are showing to improve or lessen the effects of certain cancers and mental conditions. Tomatoe juice, broccli, fruit of the upside down tree...... if it works then how much do we need to ingest, how often, etc. Research is a truly wonderful part of progressive science, but it has to be high quality and sufficient cohort size for results to be meaningful.

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Jobs

 

Job of the Week

Latest Clinical Articles

Clincal Review: Gout

Contributed by Dr Richard Stevens, consultant rheumatologist, Buckinghamshire Hospitals. Read more

Altitude-related illness

Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more

Clinical Review - Subfertility in women

Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more

Show all clinical articles

MIMS Product News

Relistor

New drug - Relistor

Wyeth has launched Relistor (methylnaltrexone bromide) for the treatment of opioid-induced constipat... Read more

Thalidomide available in the UK

Thalidomide, under the name of Thalidomide Pharmion is now commercially available in the UK. Read more

MMR catch-up programme

The DoH has written to healthcare professionals to call for urgent action to help reduce the risk of... Read more